CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
GR-MD-02 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02421094
NCT02421094Phase 2Completed
CompareCT.gov

Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Galectin Therapeutics Inc.·interventional·Posted Apr 20, 2015·Updated Oct 8, 2020

In Brief

A Phase 2 clinical trial evaluating GR-MD-02 and Placebo for Nonalcoholic Steatohepatitis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

A Randomized, Controlled, Double-blind, Parallel Group, Single Center Phase 2 Clinical Trial to Evaluate Multiple Non-Invasive Liver Fibrosis Imaging Methods in the Assessment of the Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis in Patients with NASH with Advanced Fibrosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 20, 2015
Enrollment StartSep 1, 2015
Primary CompletionSep 27, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.2 years ago

Interventions

GR-MD-02drug

GM-MD-02 active

Placebodrug

Placebo